Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | TPMT | P51580 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368821 | 0.88 | CA12 (0.67) | CA12CA1CA2CA4CA6 | |
| SCHEMBL8085144 | 0.88 | PPARA (0.58) | CA12CA1CA2CA4CA6 | |
| SCHEMBL6343700 | 0.87 | ALDH1A1 (0.65) | HTTMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL3543244 | 0.85 | MAPT (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20058880 | 0.85 | MAPK1 (0.60) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9165101 | 0.84 | TSHR (0.63) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2935777 | 0.83 | CA12 (0.65) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9374602 | 0.83 | GSK3B (0.50) | TSHRALDH1A1MEN1KMT2AALOX5 | |
| SCHEMBL2936640 | 0.83 | CA12 (0.56) | CA12CA1CA2CA4CA6 | |
| SCHEMBL8891893 | 0.83 | PDE4A (0.57) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112759672-B | Solid catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-6444670-B2 | ENZYME INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES; ANTI-DIABETIC AGENTS; TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH OBESITY, GLUCOSE INTOLERANCE, DIABETES MELLITUS, HYPERTENSION AND ISCHEMIC DISEASES OF VESSELS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020002187-A1 | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia | WYETH | 2002-01-03 | — | — | US | disclosed |
| US-6251936-B1 | ADMINISTERING TO THE PATIENT SUFFERING FROM METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA A BENZENE OR PYRIDINE SUBSTITUTED INDOLE OR BENZOTHIOPHENE DERIVATIVES OR SALTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-26 | — | — | US | disclosed |
| EP-1077969-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061435-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002187-A1 | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia | IRS1, INSR, GPR119 | CA12 3942/4885CA1 3931/4885CA2 2266/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | CA12 3880/4885CA1 4363/4885CA2 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.